Phase 2 Melanoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with uveal melanoma (a type of eye cancer) that has spread to other parts of the body or cannot be surgically removed, confirmed through a tissue or cell sample.
- People who carry a specific genetic marker called HLA-A*02:01 (a blood test can check for this).
- People who are generally able to carry out daily activities with little to no limitation, based on a standard medical scoring system (ECOG score of 0 or 1).
- People whose cancer continued to grow or spread while being treated with a drug called Tebentafusp on its own, and who have not received any other systemic (whole-body) cancer treatments since then.
Who may not be able to join:
- People who have cancer that has spread to the brain or spinal cord and has not been treated, or is causing symptoms — though people with previously treated brain lesions that have been stable for at least 4 weeks may be considered, provided certain additional conditions are met (confirm with trial site).
- People who have taken steroid medications or other drugs that suppress the immune system within 2 weeks before the planned start of the trial, with some limited exceptions for low-dose steroids used for a stable hormonal condition, or for local steroid treatments such as eye drops, joint injections, or inhalers.
- People whose overall health condition, in their treating doctor's judgement, would make participation unsafe, make it difficult to follow the trial procedures, or would affect how results are interpreted.
- People with certain chronic viral infections — though the trial notes that testing for HIV, hepatitis B, or hepatitis C is not required before joining unless a doctor considers it clinically necessary (confirm with trial site for full details).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Anthony Joshua, FRACP, St Vincent's Hospital, Sydney
Phone: 61293555655
Australian sites
0293555611
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
2 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Safety of Combination therapy
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.